Perioperative IMFINZI® (durvalumab) approved in the US in novel regimen with neoadjuvant enfortumab vedotin-ejfv for patients with muscle-invasive bladder cancer
3 outletsin 1 language and 1 countryFirst reported , latest
Every report 3 reports
- FDA approves durvalumab with enfortumab vedotin-ejfv for muscle invasive bladder cancer
United States Food and Drug AdministrationUS
Add to CRM